Table 1.
Baseline Characteristics of Patients With and Without AKI After CAR-T Therapy
| All Patients (N = 78) | AKI (n = 15) | No AKI (n = 63) | P | |
|---|---|---|---|---|
| Age, y | 60 ± 13 | 60 ± 12 | 60 ± 14 | 0.9 |
| Baseline Scr, mg/dL | 0.8 ± 0.2 | 0.9 ± 0.3 | 0.8 ± 0.2 | 0.5 |
| Baseline eGFR, mL/min/1.73 m2 | 109 ± 17 | 108 ± 18 | 109 ± 17 | 0.8 |
| Male sex | 50 (64%) | 10 (67%) | 40 (63%) | 0.8 |
| Race | 0.8 | |||
| White | 66 (85%) | 13 (87%) | 53 (84%) | |
| Black | 1 (1%) | 0 (0%) | 1 (2%) | |
| Hispanic | 3 (4%) | 0 (0%) | 3 (5%) | |
| Asian | 2 (2%) | 0 (0%) | 2 (3%) | |
| Other/unknown | 6 (8%) | 2 (13%) | 4 (6%) | |
| Cirrhosis | 1 (1%) | 1 (7%) | 0 (0%) | 0.2 |
| Hypertension | 20 (26%) | 4 (27%) | 16 (25%) | 0.9 |
| Diabetes | 9 (12%) | 3 (20%) | 6 (10%) | 0.4 |
| Coronary artery disease | 6 (8%) | 2 (13%) | 4 (6%) | 0.05 |
| Congestive heart failure | 4 (5%) | 1 (7%) | 3 (5%) | 0.3 |
| ACEi/ARB use | 7 (9%) | 1 (7%) | 6 (10%) | 0.7 |
| CAR type | 0.8 | |||
| Axicabtagene ciloleucel (Yescarta) | 69 (88%) | 14 (93%) | 55 (87%) | |
| Tisgenlecleucel (Kymriah) | 9 (12%) | 1 (7%) | 8 (13%) | |
| Lactate dehydrogenase, U/L | 379 ± 316 | 540 ± 531 | 340 ± 228 | 0.05 |
Note: Values presented as mean ± standard deviation or count (percent).
Abbreviations: ACEi, angiotensin converting-enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor blocker; CAR, chimeric antigen receptor; CAR-T, chimeric antigen receptor T-cell; eGFR, estimated glomerular filtration rate; Scr, serum creatinine.